Delineating the clinical and molecular heterogeneity of fatty liver disease to inform treatment

超重导致的脂肪肝影响着三分之一的澳大利亚成年人。这种疾病没有治疗方法，许多患者发展为肝功能衰竭或肝癌。在临床上，这种疾病的特点是显著的异质性，这对开发生物标记物和治疗方法是一个挑战。为了迈向精确医学，该项目将开展一个跨学科的项目，该项目将拥抱疾病的复杂性，并将环境和遗传风险与数学建模的能力相结合。

Fatty liver disease from excess weight affects 1 in 3 adult Australians. The disease has no treatments and many patients develop liver failure or liver cancer. Clinically, the disease is characterized by marked heterogeneity, a challenge for developing biomarkers and treatments. To move towards precision medicine, this project will undertake an inter-disciplinary program that embraces disease complexity and integrates environmental and genetic risk with the power of mathematical modelling.